Literature DB >> 23217528

Complications related to therapeutic anticoagulation in total hip arthroplasty.

Catherine J McDougall1, Hamish S Gray, Philip M Simpson, Sarah L Whitehouse, Ross W Crawford, William J Donnelly.   

Abstract

Bleeding-related wound complications cause significant morbidity in lower limb arthroplasty surgery. Patients who require therapeutic anticoagulation in the perioperative period are potentially at higher risk for these complications. This is a retrospective case-control study reviewing all primary total hip arthroplasties performed in a single center during a 5-year period and comparing outcomes of the patients on warfarin with a double-matched control group of patients not on warfarin. The warfarin group had a significantly higher risk of deep joint infection (9% vs 2.2%), hematoma/wound ooze (28% vs 4%), and superficial infection (13.5% vs 2.2%). Managing patients undergoing total hip arthroplasty with therapeutic anticoagulation is a balance between the risk of thromboembolic disease and bleeding-related complications. Improved understanding of this risk will better allow patients to make an informed decision regarding their elective arthroplasty surgery.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23217528     DOI: 10.1016/j.arth.2012.06.001

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  9 in total

1.  The use of warfarin for DVT prophylaxis following hip and knee arthroplasty: how often are patients within their target INR range?

Authors:  Denis Nam; Anita Sadhu; Jeffrey Hirsh; James A Keeney; Ryan M Nunley; Robert L Barrack
Journal:  J Arthroplasty       Date:  2014-09-06       Impact factor: 4.757

2.  Mobile Compression Reduces Bleeding-related Readmissions and Wound Complications After THA and TKA.

Authors:  Diren Arsoy; Nicholas J Giori; Steven T Woolson
Journal:  Clin Orthop Relat Res       Date:  2018-02       Impact factor: 4.176

3.  Neural network prediction of 30-day mortality following primary total hip arthroplasty.

Authors:  Safa C Fassihi; Abhay Mathur; Matthew J Best; Aaron Z Chen; Alex Gu; Theodore Quan; Kevin Y Wang; Chapman Wei; Joshua C Campbell; Savyasachi C Thakkar
Journal:  J Orthop       Date:  2021-11-25

4.  Multimodal Thromboprophylaxis in Patients With a History of Venous Thromboembolism Undergoing Primary and Revision Knee Arthroplasty.

Authors:  Drake G LeBrun; Eduardo A Salvati; Alejandro Gonzalez Della Valle
Journal:  HSS J       Date:  2021-11-08

Review 5.  Patient, Surgery, and Hospital Related Risk Factors for Surgical Site Infections following Total Hip Arthroplasty.

Authors:  Georgios Triantafyllopoulos; Ottokar Stundner; Stavros Memtsoudis; Lazaros A Poultsides
Journal:  ScientificWorldJournal       Date:  2015-05-14

6.  Low dose aspirin is effective in preventing venous thromboembolism in patients undergoing primary total knee arthroplasty.

Authors:  David B Merkow; Alex Tang; Richard Iorio; James D Slover; Joseph A Bosco; Ran Schwarzkopf
Journal:  J Orthop       Date:  2021-02-12

7.  Bridging therapy for oral anticoagulation increases the risk for bleeding-related complications in total joint arthroplasty.

Authors:  Martijn Haighton; Diederik H R Kempen; Nienke Wolterbeek; Louis N Marting; Martijn van Dijk; Remmelt M R Veen
Journal:  J Orthop Surg Res       Date:  2015-09-17       Impact factor: 2.359

8.  Factors Affecting Length of Hospital Stay and Mortality in Infected Diabetic Foot Ulcers Undergoing Surgical Drainage without Major Amputation.

Authors:  Tae Gyun Kim; Sang Young Moon; Moon Seok Park; Soon-Sun Kwon; Ki Jin Jung; Taeseung Lee; Baek Kyu Kim; Chan Yoon; Kyoung Min Lee
Journal:  J Korean Med Sci       Date:  2015-12-24       Impact factor: 2.153

9.  Thromboembolic and major bleeding events in relation to perioperative bridging of vitamin K antagonists in 649 fast-track total hip and knee arthroplasties.

Authors:  Christoffer C Jørgensen; Henrik Kehlet
Journal:  Acta Orthop       Date:  2016-10-19       Impact factor: 3.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.